ICU Medical, Inc. (NASDAQ:ICUI) Stock Has Average Target Price of $192.80 According to Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on ICU Medical, with four buy, two strong-buy and three hold ratings. The average 12-month price target is $192.80, implying upside from the reported $168.65 share price.
• ICU Medical exceeded quarterly expectations, reporting $2.37 EPS versus the $1.91 consensus and revenue of $547.88 million versus $533.44 million expected. Revenue rose 0.5% year over year, while management issued fiscal 2026 EPS guidance of $8.60–$9.00.
• Institutional investors own 96.1% of the stock, while insiders sold 21,830 shares worth about $3.9 million during the last quarter. The stock trades at a high valuation, with a reported P/E ratio of 142.92.

Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $192.80.

Several brokerages recently weighed in on ICUI. Zacks Research downgraded ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Needham & Company LLC boosted their target price on ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. BTIG Research increased their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th.

ICU Medical Trading Up 1.4%

NASDAQ ICUI opened at $168.65 on Friday. ICU Medical has a 52 week low of $113.37 and a 52 week high of $192.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The stock's 50 day moving average price is $164.60 and its two-hundred day moving average price is $148.83. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of 142.92, a PEG ratio of 2.09 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analysts' expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts anticipate that ICU Medical will post 7.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the transaction, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ben Sousa sold 2,250 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider owned 3,076 shares of the company's stock, valued at approximately $548,512.32. The trade was a 42.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 21,830 shares of company stock worth $3,905,003 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Several institutional investors have recently modified their holdings of ICUI. Allworth Financial LP bought a new stake in shares of ICU Medical in the 2nd quarter worth approximately $26,000. Versant Capital Management Inc lifted its position in shares of ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 65 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of ICU Medical during the 2nd quarter worth $51,000. Rockefeller Capital Management L.P. increased its holdings in ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 146 shares during the last quarter. Finally, Nykredit A S bought a new stake in ICU Medical in the 2nd quarter valued at about $135,000. 96.10% of the stock is owned by institutional investors.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.